Cardio Poll: ODYSSEY OUTCOMES - will Alirocumab (a PCSK-9 inhibitor) improve cardiovascular outcomes in patients with a recent acute coronary syndrome?
How do you think novel evidence from this late breaking trial to be presented at ACC.18 will impact clinical practice? Compare your answers with those of the PCRonline community!
The ODYSSEY OUTCOMES trial will test the hypothesis that Alirocumab (a PCSK-9 inhibitor that further reduces LDL cholesterol) improves cardiovascular outcomes in patients with a recent acute coronary syndrome (less than 1 year).
More about this trial:
- Number of participants: 18,000 patients
- Follow-up: at least 2 years
- Primary endpoint: death for coronary heart disease, myocardial infarction, hospitalization for unstable angina or ischemic stroke.